Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Mar 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-02-25

Reporting Person: ANDREWS RONALD ASBURY (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-25	Employee Stock Option (right to buy)	$5.34	A	500000	Acquired	2031-02-24	Common Stock (500000)	Direct

Footnotes

F1: Vesting: Twenty-five percent of the options will vest and thereby become exercisable upon completion of one year of service from the date of grant, and the balance of the options will vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, subject to his continued service as an employee on the applicable vesting date.